WEALTHARC
17.1.2024 07:44:34 CET | Business Wire | Press release
WealthArc, a Swiss born global wealth data management solution provider, has partnered with ZeroLink, a pioneering company in neurosymbolic KGQA technology, to develop WealthArc AI & Analytics – a cutting-edge machine learning-powered “Chat with your data” service tailored for the wealth management space.
The integration of ZeroLink's technology in the development of WealthArc AI & Analytics enables a game-changing approach for wealth management to effortlessly access, navigate, and comprehend complex data sets.
WealthArc empowers wealth managers, family offices, trustees and other wealth owners with a state-of-the-art data management platform aggregating globally over 200k positions every day.
With the increasing amount of wealth data available, the barrier to retrieve actionable insights is increasing. WealthArc recognized this pressing issue and sought to offer an innovative solution that would allow individuals and institutions to interact with wealth data in an easy and effective manner.
WealthArc’s Wealth Data Management, powered by a proprietary data aggregation engine with over 125 API connections and 99.3% accuracy, is highly recognized by the market, especially in data cleansing, reconciliation and intelligent reporting.
WealthArc’s App is multi-custodian and multi-currency driven solution that is intuitive and easy to use, customizable, globally scalable and with a high level of data quality. It ensures that its clients have access to up-to-date and accurate intelligent information, allowing them to make informed decisions that drive positive outcomes and build their wealth.
"We are thrilled to partner with ZeroLink to introduce WealthArc AI & Analytics solution to the wealth management industry," said Radomir Mastalerz, CEO of WealthArc. "The solution powered by ZeroLink will revolutionize the way portfolio managers, as well as wealth owners, interact with wealth data; ultimately elevating the level of service and raising the bar for the wealth management space as a whole.”
ZeroLink’s novel technology is a knowledge graph question/answering (KGQA) and knowledge modelling platform that utilizes machine learning to provide fast, accurate, and explainable answers to complex questions with reasoning that can be customized by users.
ZeroLink can translate structured data and unstructured text into a computable knowledge graph that allows users, such as wealth managers, to ask questions in conversational manner such as “What is my best performing portfolio?” or “What was the currency exchange rate impact on my portfolios?” and receive accurately sourced answers. What enables this ability is ZeroLink’s knowledge graph and ontology - containing a curated collection of over 17 billion entities, facts, attributes, relations, and reasoners that make up a fundamental world model that can serve as the foundation to ground user knowledge bases.
Current solutions for “Chat with your data” often use LLMs (Large Language Models) and have severe problems with AI hallucinations and an inability to deal with numbers – leading to major challenges to widespread adoption.
“We are excited to partner with the WealthArc team to offer a solution that can work with the sort of data that others simply cannot,” said Darren Tseng, CEO of ZeroLink. “Instead of training these models on massive corpuses of data to improve accuracy, our technology enables natural language querying from your existing data and is also better for data privacy as a result.”
To learn more about WealthArc, please visit https://www.wealtharc.com/.
To keep updated on ZeroLink KGQA technology, please sign up at https://zerolink.io/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240104094862/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
